Matinas BioPharma Holdings (MTNB) Revenue (2015 - 2023)

Matinas BioPharma Holdings (MTNB) has reported Revenue for 8 consecutive years, with $1.1 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Revenue changed N/A year-over-year to $1.1 million in Q1 2023; TTM through Dec 2023 was $1.1 million, a 65.63% decrease from a year earlier, with the FY2023 full-year figure at $1.1 million, down 65.62% from the prior year.
• Revenue was $1.1 million for Q1 2023 at Matinas BioPharma Holdings, up from $1.1 million in the prior quarter.
• Over five years, Revenue peaked at $1.1 million in Q1 2023 and troughed at -$333.0 in Q4 2021.
• A 5-year average of $507349.4 and a median of $95833.0 in 2020 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 100.53% in 2021 and soared 319319.22% in 2022, its largest moves.
• Over 5 years, Revenue stood at $89812.0 in 2019, then slumped by 30.41% to $62500.0 in 2020, then slumped by 100.53% to -$333.0 in 2021, then soared by 319319.22% to $1.1 million in 2022, then climbed by 3.1% to $1.1 million in 2023.
• The last three Revenue figures came in at $1.1 million (Q1 2023), $1.1 million (Q4 2022), and $1.1 million (Q3 2022), per Business Quant data.